Cost-effectiveness analysis of adding neoadjuvant chemotherapy with pertuzumab, in patients with HER2+breast cancer in Spain

被引：0
|
作者：
Abanell, J.
Ciruelos, E.
De la Haba, J.
Martin, M.
Munoz-Molina, B.
De Salas-Cansado, M.
Colomer, R.
机构：
[1] Hosp del Mar, Barcelona, Spain
[2] Hosp Univ 12 Octubre, Madrid, Spain
[3] Hosp Univ Reina Sofia, Cordoba, Spain
[4] Roche Farma SA, Madrid, Spain
[5] Hosp Univ La Princesa, Madrid, Spain
[6] Hosp Univ Gregorio Maranon, Madrid, Spain
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P3-12-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-12-02
引用
收藏
页数：2
相关论文
共 50 条
  • [1] COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN
    Colomer, R.
    Ciruelos, E.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Albanell, J.
    VALUE IN HEALTH, 2016, 19 (07) : A740 - A740
  • [2] COST-ESTIMATE OF ADDING NEOADJUVANT PERTUZUMAB FOR THE TREATMENT OF HER2+BREAST CANCER IN AN INSTITUTION IN PORTUGAL
    Borges, A.
    Pereira, F.
    Redondo, P.
    Antunes, L.
    Vieira, C.
    Antunes, P.
    Bento, M. J.
    Sousa, S.
    Machado Lopes, J.
    Goncalves, F. R.
    Abreu de Sousa, J.
    Pereira, D.
    Borges, M.
    VALUE IN HEALTH, 2019, 22 : S475 - S475
  • [3] ADDING PERTUZUMAB IN NEOADJUVANT TREATMENT OF PATIENTS WITH HER2+ BREAST CANCER IN SPAIN: A COST OFFSETS STUDY
    Albanell, J.
    Ciruelos, E.
    Colomer, R.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Tournier, C.
    Thuresson, P.
    Schleich, W.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2015, 117 : 42 - 42
  • [4] COST - EFFECTIVENESS ANALYSIS OF PERTUZUMAB AS FIRST LINE NEOADJUVANT TREATMENT OPTION FOR PATIENTS HER2+BREAST CANCER IN REPUBLIC OF MACEDONIA
    Nestorovska, Kapedanovska A.
    Sterjev, Z.
    Naumovska, Z.
    Dimovski, A.
    Grozdanova, A.
    Suturkova, L.
    VALUE IN HEALTH, 2018, 21 : S29 - S29
  • [5] Cost-effectiveness of pertuzumab in HER2+metastatic breast cancer
    Qian, Y.
    Durkee, B. Y.
    Pollom, E. L.
    King, M.
    Dudley, S. A.
    Shaffer, J. B.
    Chang, D. T.
    Gibbs, I. C.
    Goldhaber-Fiebert, J. D.
    Horst, K. C.
    CANCER RESEARCH, 2016, 76
  • [6] COST-EFFECTIVENESS OF INNOVATIVE TREATMENTS OF HER2+BREAST CANCER IN PERU
    Delgado, M. F.
    Postigo, R.
    VALUE IN HEALTH, 2023, 26 (06) : S164 - S164
  • [7] COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE NEOADJUVANT TREATMENT OF HER2-POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN CHINA
    Li, H.
    Guan, X.
    Chen, Q.
    Hao, C.
    Li, J.
    Wang, Y.
    Zhang, J.
    Li, K.
    Liu, C.
    Chu, Y.
    Ma, A.
    VALUE IN HEALTH, 2019, 22 : S480 - S480
  • [8] Cost-Effectiveness Analysis Of Pertuzumab For Metastatic Her2-Positive Breast Cancer In Japan
    Tange, C.
    Kunisawa, S.
    Maeda, S.
    Shimozuma, K.
    VALUE IN HEALTH, 2015, 18 (07) : A456 - A457
  • [9] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2+breast cancer.
    Garrison, L. P., Jr.
    Perez, E. A.
    Dueck, A.
    Lalla, D.
    Paton, V.
    Lubeck, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 306S - 306S
  • [10] Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer
    Dai, Wei Fang
    Beca, Jaclyn M.
    Nagamuthu, Chenthila
    Liu, Ning
    de Oliveira, Claire
    Earle, Craig C.
    Trudeau, Maureen
    Chan, Kelvin K. W.
    JAMA ONCOLOGY, 2022, 8 (04) : 597 - 606
12345